Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMA COMPOUND W/ CODEINE vs OXYCODONE AND ASPIRIN (HALF-STRENGTH)
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Soma Compound with Codeine is a combination of carisoprodol, aspirin, and codeine. Carisoprodol is a centrally acting skeletal muscle relaxant whose exact mechanism is unknown, but it is believed to act via interneuronal depression in the spinal cord and reticular formation. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: postoperative pain, dental pain, chronic pain
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg / codeine phosphate 16 mg) orally every 4-6 hours as needed for pain, not to exceed 4 tablets per day.
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
Carisoprodol: 1-2 hours. Meprobamate (active metabolite): 10-12 hours. Codeine: 2.5-3.5 hours; prolonged in renal impairment. Clinical context: steered by meprobamate half-life for repeated dosing.
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
GFR 30-60 m L/min: Avoid use due to aspirin component; if necessary, reduce dose by 50% and monitor for toxicity. GFR <30 m L/min: Contraindicated due to risk of aspirin accumulation and codeine metabolite accumulation.
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
Concomitant use of codeine with all CYP3A4 inducers may lead to withdrawal symptoms or reduced efficacy. Concomitant use with CYP3A4 inhibitors may increase codeine plasma concentrations and prolong adverse reactions. Codeine is contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy due to risk of respiratory depression and death. Avoid use in adolescents with risk factors for respiratory depression.
First trimester: Risk of neural tube defects and congenital malformations associated with codeine (FDA Pregnancy Category D). Carisoprodol: limited data, but caution due to potential metabolic effects. Second and third trimesters: Chronic use of codeine may lead to fetal opioid dependence and neonatal abstinence syndrome (NAS). Carisoprodol may cause fetal respiratory depression and withdrawal.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
Soma Compound with Codeine contains carisoprodol (a centrally acting muscle relaxant metabolized to meprobamate, a controlled substance), aspirin, and codeine. Avoid in patients with G6PD deficiency, bleeding disorders, or asthma. Carisoprodol carries high abuse potential; limit to short-term use (2-3 weeks). Codeine is a prodrug requiring CYP2D6 metabolism; ultra-rapid metabolizers risk toxicity. Aspirin increases bleeding risk; avoid with anticoagulants or in children with viral illness (Reye's syndrome).
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
No interactions on record
No interactions on record
SOMA COMPOUND W/ CODEINE and OXYCODONE AND ASPIRIN (HALF-STRENGTH) are distinct pharmacological agents. SOMA COMPOUND W/ CODEINE belongs to the Opioid Agonist class and is primarily used for Relief of discomfort associated with acute, painful musculoskeletal conditionsOff-label: postoperative pain, dental pain, chronic pain. OXYCODONE AND ASPIRIN (HALF-STRENGTH) belongs to the Opioid Agonist class and is primarily used for Moderate to moderately severe pain (when combination therapy is appropriate)Off-label: acute pain, chronic pain. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SOMA COMPOUND W/ CODEINE carries a safety status of Category D/X, whereas OXYCODONE AND ASPIRIN (HALF-STRENGTH) safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Carisoprodol is hepatically metabolized via CYP2C19 to meprobamate. Aspirin is hydrolyzed to salicylic acid and conjugated in the liver. Codeine is metabolized by CYP3A4 to norcodeine, CYP2D6 to morphine, and other pathways.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Carisoprodol is hepatically metabolized; approximately 60-70% of a dose is excreted renally as meprobamate and other metabolites, with less than 1% unchanged. Codeine is renally excreted as codeine (5-17%), morphine (10-15%), and conjugates (up to 70%). Biliary/fecal elimination is minimal.
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
Carisoprodol: 60% (primarily albumin). Codeine: 7-25% (mainly albumin).
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
Carisoprodol: Vd ~2.5 L/kg; indicates extensive tissue distribution. Codeine: Vd ~3-6 L/kg; high tissue binding.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
Oral: carisoprodol 90-100%; codeine 50-90% (first-pass metabolism).
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
Child-Pugh Class A: No adjustment recommended, but use with caution. Child-Pugh Class B: Reduce dose by 50% due to impaired metabolism of codeine and carisoprodol; monitor for sedation and respiratory depression. Child-Pugh Class C: Avoid use due to high risk of toxicity.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
Not recommended for pediatric use due to risk of Reye's syndrome (aspirin) and respiratory depression (codeine); contraindicated in children <12 years for codeine; avoid in all pediatric patients.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
Start at lower dose (1 tablet every 6-8 hours) due to increased sensitivity to CNS effects and renal impairment; monitor for sedation, falls, and gastrointestinal bleeding (aspirin).
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
Risk of respiratory depression, drug dependence, abuse potential, impaired mental/physical abilities, severe hepatic injury from aspirin, Reye syndrome in children, anaphylaxis, bleeding risk (aspirin), serotonin syndrome (concomitant serotonergic drugs), adrenal insufficiency, severe hypotension, seizure risk, withdrawal with discontinuation.
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Hypersensitivity to any component, acute porphyria (carisoprodol), children <12 years, post-tonsillectomy/adenoidectomy in children <18 years, significant respiratory depression, acute or severe bronchial asthma, GI obstruction, suspected surgical abdomen, bleeding disorders (aspirin), concomitant use of MAOIs, use within 14 days of MAOIs.
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Avoid alcohol and products containing aspirin or other salicylates. Aspirin component can irritate gastric mucosa; take with food or milk to reduce GI upset. No significant food-drug interactions for carisoprodol or codeine beyond standard CNS depressant avoidance.
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
Both codeine and carisoprodol are excreted into breast milk. Codeine: M/P ratio ~1.5, risk of infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Carisoprodol: M/P ratio not well defined, but considered present. Contraindicated during breastfeeding due to potential for infant opioid toxicity and sedation.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Increased clearance of carisoprodol during pregnancy due to enhanced hepatic metabolism may require dose adjustment, but specific guidelines are lacking. Codeine: Addictive potential persists; use lowest effective dose for shortest duration. Avoid in third trimester due to risk of NAS.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
Take exactly as prescribed; do not increase dose or frequency without doctor approval due to risk of dependence.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this medication, as it can increase sedation and respiratory depression risk.,Stop taking and seek medical help if you experience signs of bleeding (easy bruising, black/tarry stools, vomiting blood), allergic reaction (rash, swelling, difficulty breathing), or slow/shallow breathing.,Store out of reach of children; accidental overdose of aspirin or codeine can be fatal.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).